<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297529</url>
  </required_header>
  <id_info>
    <org_study_id>20120328</org_study_id>
    <secondary_id>2014-002834-30</secondary_id>
    <nct_id>NCT02297529</nct_id>
  </id_info>
  <brief_title>Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma</brief_title>
  <official_title>A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The study is a phase 3b, multicenter, open-label, single-arm study designed to provide&#xD;
      expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected&#xD;
      stage IIIB to IVM1c melanoma. The study will also evaluate the safety and tolerability of&#xD;
      Talimogene Laherparepvec.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3b, multicenter, open-label, single-arm, expanded access study of talimogene&#xD;
      laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma in&#xD;
      select European countries. Subjects with unresected stage lllB-IVM1c melanoma who are not&#xD;
      eligible for or cannot access ongoing talimogene laherparepvec clinical trials and who meet&#xD;
      the eligibility criteria outlined will be considered for participation in this protocol.&#xD;
      Eligible subjects will be treated with talimogene laherparepvec until the subject has&#xD;
      achieved a complete response, all injectable tumors have disappeared, clinically relevant&#xD;
      (resulting in clinical deterioration or requiring change of therapy) disease progression&#xD;
      beyond 6 months of therapy, intolerance of protocol treatment, or until talimogene&#xD;
      laherparepvec receives marketing authorization approval in Europe for the treatment of&#xD;
      melanoma, whichever occurs first. Subjects will be followed for safety approximately 30 (+7)&#xD;
      days after the end of treatment. Thereafter, subjects who provide consent will be followed&#xD;
      under an ongoing separate registry protocol for the long-term survival follow-up of subjects&#xD;
      treated with talimogene laherparepvec in clinical trials. The registry protocol will also&#xD;
      monitor for late and long-term adverse events thought to be potentially related to talimogene&#xD;
      laherparepvec.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Unresected Stage IIIB to IVM1c Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talimogene Laherparepvec</intervention_name>
    <description>Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide informed consent prior to initiation of any protocol-specific&#xD;
             activities/procedures.&#xD;
&#xD;
          2. Male or female age ≥ 18 years at the time of informed consent.&#xD;
&#xD;
          3. Histologically confirmed diagnosis of melanoma&#xD;
&#xD;
          4. Subject has unresected stage lllB to IVM1c melanoma regardless of prior therapy&#xD;
&#xD;
          5. Subject who is not eligible for or cannot access ongoing talimogene laherparepvec&#xD;
             clinical trials 6.Subject does not qualify for, or cannot access, other comparable or&#xD;
             satisfactory alternative therapy for stage IIIB to IVM1c melanoma&#xD;
&#xD;
        7. Candidate for intralesional therapy 8. Adequate organ function. 9. ECOG performance&#xD;
        status of 0, 1, or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically active cerebral metastases.&#xD;
&#xD;
          2. Greater than 3 visceral metastases.&#xD;
&#xD;
          3. Bone metastases&#xD;
&#xD;
          4. Primary ocular or mucosal melanoma.&#xD;
&#xD;
          5. History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis,&#xD;
             vasculitis, or other symptomatic autoimmune disease.&#xD;
&#xD;
          6. Active herpetic skin lesions or prior complications of HSV-1 infection (eg, herpetic&#xD;
             keratitis or encephalitis)&#xD;
&#xD;
          7. Known to have acute or chronic active hepatitis B or C infection&#xD;
&#xD;
          8. Known to have human immunodeficiency virus infection&#xD;
&#xD;
          9. History of other malignancy within the past 3 years&#xD;
&#xD;
         10. Female subject is pregnant or breast-feeding, or planning to become pregnant during&#xD;
             protocol treatment and through 3 months after the last dose of talimogene&#xD;
             laherparepvec&#xD;
&#xD;
         11. Female subject of childbearing potential who is unwilling to use acceptable method(s)&#xD;
             of effective contraception during protocol treatment and through 3 months after the&#xD;
             last dose of talimogene laherparepvec.&#xD;
&#xD;
         12. Subject has known sensitivity to any of the products or components to be administered&#xD;
             during dosing.&#xD;
&#xD;
         13. Subject has entered this protocol previously.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresected, Melanoma, expanded access, EU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talimogene laherparepvec</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

